



Addressing the Drug Epidemic Through PMP Data



Jason Slavoski, Pharm.D.
PMP Administrator
Delaware Division of Professional Regulation
Office of Controlled Substances



Background

- PMP statute signed 7/15/2010
- Data available from 9/1/2011
- Migrated to PMP Aware with NarxCare 11/7/2017
 - Purpose of the PMP is to reduce misuse of controlled substances and to promote improved professional practice and patient care
 - Tableau is the primary analytics tool






DELAWARE PMP

Significant Events

Delaware Prescriber Trends- Opioids





Clinical Use

- PMP Aware with NarxCare
 - Provides clinical reports and analytics to licensed providers and other authorized users
 - Patient and provider (self) controlled substance dispensation history
 - Data tables, charts, trends, alerts
 - Provider “report cards”
 - Unsolicited reporting of risky/concerning patient data
 - Integration into existing workflow of EHR/EMR/pharmacy dispensing software



PMP has become an important resource in guiding policy and public health surveillance

- Prescribing patterns and aggregate data provided to:
 - Governor and Lt. Governor's Office
 - State policy makers
 - Division of Public Health
 - State epidemiologists
- Identifiable prescriber and dispenser information *may* be provided to:
 - PMP Advisory Committee
 - Addiction Action Committee
 - Drug Overdose Fatality Review Commission



PMP Advisory Committee

- Composed of 7 members
- Provides input, advice, and guidance to the Office of Controlled Substances
 - Responsible for developing criteria for identifying those in need of referral for investigation due to apparent outlier behavior or trends
 - Has identified multiple targets of investigation which have led to disciplinary action and/or prosecution



DELAWARE PMP

PMP Advisory Committee

Outliers [REDACTED]





Drug Overdose Fatality Review Commission (DOFRC)

- Composed of 14 members including Cabinet Secretaries or Directors and Governor-appointed members representing various stakeholder groups.
- The Commission shall investigate and review the facts and circumstances of overdose deaths that occur in Delaware
 - Requests PMP reports of decedents on a quarterly basis
 - Releases annual report of key findings of their investigations



Drug Overdose Fatality Review Commission (DOFRC)

- 2021 Report
 - Sample of 130 overdose fatalities that occurred in 2019
 - Notable findings:
 - Decedents had a median of 7.5 opiate prescriptions, quantity of 304 pills, and day supply of 65.5 days.
 - 38% of decedents in the sample were unhoused or had unstable housing. Decedents without stable housing were significantly likelier to have been previously incarcerated
 - 4% of decedents in the sample had experienced one or more traumatic events—including 15% who witnessed an overdose—but only 8.5% of decedents had received counseling
 - 40% of decedents had at least one prior non-fatal overdose; some had as many as nine



Drug Overdose Fatality Review Commission (DOFRC)

- 2021 Report
 - The report makes five key recommendations:
 - Provide safe and secure housing through the empirically-backed Housing First model for unhoused or unstably housed individuals.
 - Expand Continuing Education availability for Licensed Clinicians to increase knowledge of Trauma Intervention Services
 - Intervene for those whose contact with law enforcement does not result in arrest or incarceration; and initiate substance abuse treatment services immediately following incarceration for inmates awaiting sentencing
 - **Establish a notification system within the Prescription Monitoring Program to ensure prescribers are aware of patient non-fatal overdose(s)**
 - Improve outreach and follow-up with individuals who engaged in substance abuse related treatment



Addiction Action Committee (AAC)

- Composed of 17 members including Cabinet Secretaries and Governor-appointed members representing various stakeholder groups.
 - The purpose of the Committee is to:
 - Develop and monitor a coordinated and comprehensive approach to Delaware's addiction epidemic.
 - Recommend and encourage comprehensive prevention, treatment, surveillance, and monitoring strategies to evaluate and curtail the addiction epidemic in Delaware.
 - Promote quality and accessible pain management for Delawareans.



Addiction Action Committee (AAC)


- Academic detailing
 - Partnership with Division of Public Health and their contracted vendor
 - Guided by independent body (Addiction Action Committee)
 - Purpose is to identify prescribers that may benefit from targeted education based on prescribing metrics
 - Several iterations ranging from 5-21 metrics
 - Yielded approximately 50 prescribers during first iteration and 150 during second iteration
 - New method under development




DELAWARE PMP

Academic detailing

Academic detailing tracking (round 1, Opioid Rx Count)_GRAPH (identified prescribers)



Academic detailing tracking (round 1, Cash Rx Count)_GRAPH (Identified Prescribers)





State Policy

- SB 34 was introduced and signed into law on 6/12/19 as 16 Del. C. 48B, Prescription Opioid Impact Fund
 - Legislators, advocates, manufacturers, and the public helped craft bill
 - A manufacturer of a prescription opioid must pay a prescription opioid impact fee to the State if more than 100,000 MME of the manufacturer's prescription opioid products are dispensed in this State in a quarter
 - » (b) The prescription opioid impact fee is calculated as follows:
 - (1) The impact fee is \$0.01 per MME for a prescription opioid dispensed and reported in the PMP
 - (2) The impact fee is \$0.0025 per MME for a prescription opioid that is a generic substitution
 - » (c) The Secretary of State shall calculate the total amount of the impact fee on a quarterly basis using the information in the PMP



Delaware State Senator
Stephanie Hansen, primary
sponsor



State Policy

- Prescription Opioid Impact Fund
 - Began building out immediately after bill signed
 - Built entirely using Tableau software with billing done through new DELPROS system
 - First invoices sent Q3 of 2019
 - Invoiced approximately \$3 million to date (10/13/21)
 - Collected approximately \$2.8 million to date (10/13/21)
 - Outstanding balance due to recently sent invoices
 - Small portion of revenue earmarked for administrative costs



State Policy

- Prescription Opioid Impact Fund
 - Allocation of first \$700,000 in funds for treatment of SUD
 - Funds from the Opioid Impact Fee will be targeted for four main purposes in the coming year:
 - \$300,000 will be combined with federal grant funding to help fill a critical gap in the existing system of care for people struggling with addiction issues. Interventions immediately following an overdose or other hospitalization present an effective opportunity to enroll patients in treatment programs. Currently, people discharged from the hospital are brought to a Bridge Clinic, located in each county, for screening and referrals to these programs. However, Bridge Clinics do not operate 24/7. DSAMH is currently working to address this issue through the addition of Stabilization Centers that can house and counsel clients during off-hours and weekends. Funding from the Opioid Impact Fee will help cover capital start-up costs, while the State Opioid Response federal grant will be used to fund programmatic and treatment expenses.
 - \$250,000 will be used to help people struggling with addiction issues fill gaps in the social determinants that often present roadblocks in their efforts to enter, continue and complete the treatment and recovery process. These funds will provide DSAMH with the ability to assist clients with transportation costs and transitional housing while they seek treatment, as well as additional supports for people in recovery.



State Policy

- Prescription Opioid Impact Fund
 - Funds from the Opioid Impact Fee will be targeted for four main purposes in the coming year (continued):
 - \$100,000 will be reserved to cover the Department of State's administrative expenses associated with the collection of the fee.
 - \$50,000 will be used to purchase 925 additional naloxone kits that DSAMH will make available to various community groups. Organizations can acquire these life-saving kits by contacting DSAMH. During the first three quarters of 2020, the Delaware Division of Public Health's Office of Health Crisis Response distributed nearly 6,300 naloxone kits statewide through its community partners.



Public-Facing Data Portal

- My Healthy Community, Delaware Environmental Public Health Tracking Network
 - Coronavirus Dashboard
 - Population Health Dashboard
 - Community, environmental, climate, chronic disease, **mental health and substance abuse**, infectious disease, etc.
 - PMP Data
 - » Currently includes 5 aggregated patient metrics
 - » New iteration to broaden scope of data





DELAWARE PMP

Public-Facing Data Portal

PREScription MONITORING PROGRAM

MAPS

State of Delaware Opioid Agonist Prescriptions, 2015 to 2018 ⓘ



2015

2016

2017

2018



- Help Is Here Delaware
 - <http://www.helpisherede.com>
 - Delaware's comprehensive patient and healthcare provider resource for prevention, addiction, treatment, and recovery.





PMP future data efforts

- Integration of other data sets into PMP data:
 - Non-fatal overdose data?
 - Fatal overdose data?
 - Marijuana data or indicator?
 - Criminal justice data or indicator?
- Data clean-up
- Expand EHR integration
- Expand public facing PMP data as allowed by law
- Expanded outreach efforts with partner agencies